Semax
Research OnlyA synthetic heptapeptide analogue of ACTH(4-7) with a C-terminal Pro-Gly-Pro extension, developed by Russian researchers and approved in Russia since ~1997 for stroke, cognitive impairment, and optic nerve disorders. Demonstrates nootropic and neuroprotective effects through BDNF/NGF upregulation, dopaminergic and serotonergic modulation, and anti-inflammatory mechanisms. Extensive Russian clinical research supports efficacy, particularly in stroke rehabilitation, though Western independent replication remains limited.
ACTH(4-7)PGP · Methionyl-Glutamyl-Histidyl-Phenylalanyl-Prolyl-Glycyl-Proline · MEHFPGP
8 human studies
- Preclinical
- 75%
- Human research
- 25%
Based on 32 cited sources
Numeric assessment unreviewed
A historical numeric score is recorded but has not passed a current, compound-specific assessment review. No numeric score is displayed.
This is a limitation of the numeric assessment, not a measured absence of benefit. It does not re-review the separately recorded catalogue classification or establish efficacy or safety.
Semax has a complex, multi-target mechanism of action that distinguishes it from traditional nootropics. Unlike its parent ACTH molecule, Semax does not stimulate cortisol release, making it safe for long-term neurological use.
How It Works (Simplified)
Semax acts as a “brain fertilizer and protector” through several complementary pathways:
Rapidly increases BDNF and NGF expression within minutes of administration, supporting learning, memory, neuronal survival, and recovery from injury.
Activates dopamine and serotonin systems in striatum and frontal cortex, enhancing attention, motivation, and mood without depleting neurotransmitter stores.
Suppresses pro-inflammatory cytokines (IL-1, IL-6, TNF-alpha) and chemokines following brain injury, protecting neurons from secondary damage.
Modulates hundreds of genes involved in neurotransmission, immune response, and cell survival, producing sustained benefits through transcriptional changes.
Important Limitations
- Most research originates from Russian institutions with limited Western independent replication
- Many primary studies published only in Russian, creating language barriers for verification
- Historical clinical trials may not meet current Western GLP/GCP standards
- Human pharmacokinetics and optimal dosing not fully characterized by Western standards
- No FDA or EMA regulatory pathway has been pursued
Reported positives
- Improved focus and mental clarity frequently reported
- Reduced brain fog and enhanced cognitive performance
- Mood improvement and reduced anxiety noted
- Nasal administration convenient and non-invasive
Reported negatives
- Effects short-lived requiring frequent redosing
- Hair loss reported by some long-term users
- Irritability and overstimulation at higher amounts
- Product quality varies between suppliers
“Popular nootropic in r/Nootropics and r/Peptides. Russian-approved drug with growing Western interest.”
Self-reported, unverified accounts — not clinical evidence and no substitute for the cited research. Anecdotes are prone to selection bias and placebo effects.
Based on preclinical and clinical data: Rapid BDNF/NGF upregulation begins within 30 minutes of intranasal administration. In stroke patients, early intervention shows greatest benefits. Dopamine and serotonin modulation observed.
PMID:16996037In stroke rehabilitation trials, BDNF levels increased significantly and functional recovery (Barthel scores) improved over 2-4 weeks. Anti-inflammatory effects reduce secondary brain damage. Clinical trials showed improved attention and cognitive function.
PMID:29798983Russian protocols typically use 10-14 day treatment courses. Long-term effects and optimal duration not characterized by Western standards. Some conditions may require repeated courses.
PMID:16362768Long-term maintenance protocols not well-established. Russian clinical practice suggests periodic treatment courses rather than continuous administration. Human pharmacokinetics not fully characterized.
Research-based observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
Selank
SynergisticComplementary Russian regulatory peptides - Semax provides nootropic/neuroprotective effects via BDNF while Selank offers anxiolysis via GABA. Common clinical combination in Russia.
Epithalon
CompatibleBoth Russian bioregulator peptides with different CNS targets - Semax for acute neuroprotection via BDNF, epithalon for cellular longevity via telomeres.
BPC-157
CompatibleBoth have neuroprotective properties - Semax via BDNF/NGF upregulation, BPC-157 via multiple CNS repair mechanisms. May have complementary neuroprotective effects.
Thymosin-Alpha-1
CompatibleSemax has immunomodulatory effects alongside nootropic actions; Ta1 is primarily immunomodulatory. Different primary mechanisms with potential immune synergy.
TB-500
CompatibleBoth promote tissue repair - Semax in CNS via neurotrophins, TB-500 systemically via actin regulation. Different primary targets.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
Key Studies Cited
Use the source links in the research discussion above to inspect the referenced records.
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength labels summarize the cited material for this entry and should be read alongside its population, model, and study limitations.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare Semax
Related Peptides
Alixorexton
ALKS 2680 · ALKS-2680
An oral orexin receptor 2 (OX2R) agonist developed by Alkermes for narcolepsy type 1 (NT1). Phase 2 clinical trials demonstrated improvements in excessive daytime sleepiness and cataplexy with once-daily dosing. Represents a novel approach to restore orexin signaling in patients who have lost orexin-producing neurons.
Cerebrolysin
FPF-1070 · N-PEP-12 · Renacenz
Cerebrolysin is a porcine brain-derived peptide mixture approved in 50+ countries for stroke, dementia, and traumatic brain injury. It is NOT FDA-approved in the United States despite decades of international clinical use. Contains neurotrophic peptide fragments mimicking BDNF, GDNF, NGF, and CNTF. Mixed Phase 3 results but positive meta-analyses and widespread adoption in Europe, Asia, and Latin America.
Cerluten
Brain cytamin · Cerebral peptides · A-5 brain peptides
A cytamin-class peptide supplement derived from brain tissue, part of the Russian bioregulator framework. Marketed as an oral supplement for cognitive support and neuroprotection. Contains peptide complexes rather than defined sequences. No Western clinical validation.
Cortexin
Cortexinum · Polypeptide brain extract · Bovine brain cortex polypeptides
A Russian neuropeptide complex derived from porcine or bovine cerebral cortex, approved in Russia and CIS countries for neurological conditions. Contains low molecular weight polypeptides (1,000-10,000 Da) with proposed neurotrophic and neuroprotective properties. NOT approved by FDA, EMA, or other Western regulatory agencies. Evidence comes primarily from Russian studies with limited Western validation.
Dihexa
PNB-0408 · N-hexanoic-Tyr-Ile-(6) aminohexanoic amide
An angiotensin IV analog developed by Washington State University researchers, claimed to enhance cognition through HGF/c-Met signaling. Gained attention for extreme potency claims (10 million times more potent than BDNF), but evidence is limited to rodent studies from a single research group with no human clinical trials. Sold as a research chemical with unknown safety profile.
DSIP
Delta sleep-inducing peptide · Emideltide · WAGGDASGE
DSIP (emideltide) is a nine-amino-acid peptide investigated for sleep. Small, older intravenous studies in people with insomnia produced conflicting results; benefit for insomnia has not been established. Animal findings do not establish effects in people.
Compared With
10 comparisonsConditions Studied
5 entries- Semax for Cognitive Enhancement Semax has been extensively studied for its nootropic properties, demonstrating improvements in memory, attention, and learning thr…
- Semax for Stroke Recovery Semax is approved in Russia for ischemic stroke treatment and rehabilitation. Clinical trials have demonstrated neuroprotective ef…
- Semax for Neuroprotection Semax demonstrates broad neuroprotective effects through multiple mechanisms including neurotrophin upregulation, anti-inflammator…
- Semax for Optic Nerve Disorders Semax is approved in Russia for optic nerve atrophy and has demonstrated benefits in various optic neuropathies. Clinical trials s…
- Semax for Attention Deficit Semax has theoretical potential for ADHD and attention disorders based on its dopaminergic modulation and BDNF-inducing properties…